Related Experiment Video
Updated: Apr 25, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents
Gurleen Kaur1, Mohinder P Mahajan2, Manoj K Pandey3
1School of Pharmaceutical Sciences, Apeejay Stya University, Plot No. 23, Institutional Area, Sector-32, Gurgaon 122001, India.
Abstract:
The synthesis of some novel Ospemifene derived analogs and their evaluation as anti-breast cancer agents against MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) human breast cancer cell lines are described. Few of these analogs for instance, compounds 6, 7 and 8 are shown to be more effective than recent Selective Estrogen Receptor Modulators (SERMs) i.e. Ospemifene and Tamoxifen, against these cell lines. Compound 8 was relatively more cytotoxic to MCF-7 cells similar to Ospemifene and Tamoxifen, while most potent compounds 6 and 7 were equally effective in inhibiting growth of both ER-positive and ER-negative cell lines. The observed activity profiles were further supported by the docking studies performed against estrogen receptors (ERα and ERβ). Compounds 6, 7 and 8 exhibited stronger binding affinities with both ERα and ERβ compared to Ospemifene and Tamoxifen.
Insights
Novel Ospemifene analogs show potent anti-breast cancer activity. Compounds 6 and 7 effectively inhibit both ER-positive and ER-negative breast cancer cells, outperforming existing therapies.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Pharmacology
Background:
- Selective Estrogen Receptor Modulators (SERMs) are crucial in breast cancer therapy.
- Ospemifene and Tamoxifen are established SERMs, but novel analogs are needed for improved efficacy.
- Understanding structure-activity relationships is key to developing new anti-cancer agents.
Purpose of the Study:
- To synthesize novel Ospemifene-derived analogs.
- To evaluate the anti-breast cancer efficacy of these analogs against ER-positive (MCF-7) and ER-negative (MDA-MB-231) human breast cancer cell lines.
- To investigate the binding affinities of potent analogs to estrogen receptors (ERα and ERβ).
Main Methods:
- Chemical synthesis of Ospemifene analogs.
- In vitro cytotoxicity assays using MCF-7 and MDA-MB-231 cell lines.
- Molecular docking studies against estrogen receptor alpha (ERα) and beta (ERβ).
Main Results:
- Compounds 6, 7, and 8 demonstrated significant anti-breast cancer activity.
- Compounds 6 and 7 were effective against both ER-positive and ER-negative cell lines, showing broader potential.
- Compounds 6, 7, and 8 exhibited superior binding affinities to ERα and ERβ compared to Ospemifene and Tamoxifen.
Conclusions:
- Novel Ospemifene analogs, particularly compounds 6 and 7, represent promising candidates for breast cancer treatment.
- These analogs display potent cytotoxic effects and favorable binding profiles to estrogen receptors.
- Further investigation into these analogs could lead to the development of more effective breast cancer therapies.
